1 Innovative Growth Market on the Verge of Collapse

Innovation's a key now more than ever in the medical device industry, which has been slammed by the combination of slumping prices, tough competition, and tightening hospital budgets. For top cardiovascular device makers like Covidien (NYSE: COV  ) and Medtronic (NYSE: MDT  ) , finding new treatments for growing health problems is the way to future sales -- and few developmental treatments have impressed investors and analysts recently in this industry like hypertension treatment renal denervation.

Yet renal denervation has stumbled onto hard times all of the sudden. A pivotal trial in the niche from Medtronic's Symplicitydevice ended in failure. Now Covidien recently announced that it will cease making its own European regulator-approved renaldenervation device, the OneShot, and fellow cardiovascular leader Boston Scientific (NYSE: BSX  ) is putting its own trial on hold until it can review Medtronic's data.

Is renal denervation dead in the water for innovation-minded device makers? In the video below, Motley Fool contributor Dan Carroll takes you through what you need to know about the stunning fall of this once-red hot growth niche -- and whether or not renal denervation can still become a promising part of medical device makers' portfolios.

The hidden health care growth opportunity that could jump-start your portfolio's profits
While renal denervation's fighting to stay alive, the best way to play the health care space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2807690, ~/Articles/ArticleHandler.aspx, 8/29/2015 5:15:34 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Carroll

Dan began writing for the Motley Fool in 2012. He is a health care specialist who also follows the defense industry along with tracking the broader U.S. and international markets.

Today's Market

updated 19 hours ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
COV $0.00 Down +0.00 +0.00%
Covidien CAPS Rating: *****
MDT $73.56 Up +0.04 +0.05%
Medtronic CAPS Rating: ****
STJ $72.62 Up +0.19 +0.26%
St. Jude Medical,… CAPS Rating: *****
BSX $17.07 Up +0.13 +0.77%
Boston Scientific… CAPS Rating: ***